Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Study of the Efficacy, Safety, and Immunogenicity of CMAB015 and Secukinumab in Adult Patients With Moderate-severe Chronic Plaque Psoriasis

NCT06398652 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT06398652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06398652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Study of the Efficacy, Safety, and Immunogenicity of CMAB015 and Secukinumab in Adult Patients With Moderate-severe Chronic Plaque Psoriasis
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2024
Completion date
March 19, 2026
Enrollment
336 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis